4,4'-Diaponeurosporen-4-al | 59057-70-4

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: 4,4'-Diaponeurosporen-4-al
• 英文别名: (2E,4E,6E,8E,10E,12E,14E,16E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,4,6,8,10,12,14,16,18,22-decaenal
• CAS: 59057-70-4
• 化学式: C₃₀H₄₀O
• 分子量: 416.6
• InChiKey: XDVAYNOICRRSLG-ZVLLIQJTSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  10.4
• 重原子数：
  31
• 可旋转键数：
  12
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  4,4'-Diaponeurosporen-4-al 、 水 、 nicotinamide adenine dinucleotide 生成 4,4'-Diaponeurosporenoate 、 氢(+1)阳离子 、 NADH
  参考文献：
  名称：

  Functional Expression and Extension of Staphylococcal Staphyloxanthin Biosynthetic Pathway in Escherichia coli

  摘要：

  The biosynthetic pathway for staphyloxanthin, a C-30 carotenoid biosynthesized by Staphylococcus aureus, has previously been proposed to consist of five enzymes (CrtO, CrtP, CrtQ, CrtM, and CrtN). Here, we report a missing sixth enzyme, 4,4'-diaponeurosporen-aldehyde dehydrogenase (AldH), in the staphyloxanthin biosynthetic pathway and describe the functional expression of the complete staphyloxanthin biosynthetic pathway in Escherichia coli. When we expressed the five known pathway enzymes through artificial synthetic operons and the wild-type operon (crtOPQMN) in E. coli, carotenoid aldehyde intermediates such as 4,4'-diaponeurosporen-4-al accumulated without being converted into staphyloxanthin or other intermediates. We identified an aldH gene located 670 kilobase pairs from the known staphyloxanthin gene cluster in the S. aureus genome and an aldH gene in the non-staphyloxanthin-producing Staphylococcus carnosus genome. These two putative enzymes catalyzed the missing oxidation reaction to convert 4,4'-diaponeurosporen-4-al into 4,4'-diaponeurosporenoic acid in E. coli. Deletion of the aldH gene in S. aureus abolished staphyloxanthin biosynthesis and caused accumulation of 4,4'-diaponeurosporen-4-al, confirming the role of AldH in staphyloxanthin biosynthesis. When the complete staphyloxanthin biosynthetic pathway was expressed using an artificial synthetic operon in E. coli, staphyloxanthin-like compounds, which contained altered fatty acid acyl chains, and novel carotenoid compounds were produced, indicating functional expression and coordination of the six staphyloxanthin pathway enzymes.

  DOI：

  10.1074/jbc.m112.343020
• 作为产物：
  描述：

  AH₂ 、 4,4'-二脱辅基链孢红素 、 氧气 生成 4,4'-Diaponeurosporen-4-al 、 A 、 水
  参考文献：
  名称：

  Functional Expression and Extension of Staphylococcal Staphyloxanthin Biosynthetic Pathway in Escherichia coli

  摘要：

  The biosynthetic pathway for staphyloxanthin, a C-30 carotenoid biosynthesized by Staphylococcus aureus, has previously been proposed to consist of five enzymes (CrtO, CrtP, CrtQ, CrtM, and CrtN). Here, we report a missing sixth enzyme, 4,4'-diaponeurosporen-aldehyde dehydrogenase (AldH), in the staphyloxanthin biosynthetic pathway and describe the functional expression of the complete staphyloxanthin biosynthetic pathway in Escherichia coli. When we expressed the five known pathway enzymes through artificial synthetic operons and the wild-type operon (crtOPQMN) in E. coli, carotenoid aldehyde intermediates such as 4,4'-diaponeurosporen-4-al accumulated without being converted into staphyloxanthin or other intermediates. We identified an aldH gene located 670 kilobase pairs from the known staphyloxanthin gene cluster in the S. aureus genome and an aldH gene in the non-staphyloxanthin-producing Staphylococcus carnosus genome. These two putative enzymes catalyzed the missing oxidation reaction to convert 4,4'-diaponeurosporen-4-al into 4,4'-diaponeurosporenoic acid in E. coli. Deletion of the aldH gene in S. aureus abolished staphyloxanthin biosynthesis and caused accumulation of 4,4'-diaponeurosporen-4-al, confirming the role of AldH in staphyloxanthin biosynthesis. When the complete staphyloxanthin biosynthetic pathway was expressed using an artificial synthetic operon in E. coli, staphyloxanthin-like compounds, which contained altered fatty acid acyl chains, and novel carotenoid compounds were produced, indicating functional expression and coordination of the six staphyloxanthin pathway enzymes.

  DOI：

  10.1074/jbc.m112.343020

文献信息

• Hydroxylated nebivolol metabolites
  申请人：O'Donnell P. John

  公开号：US20070014733A1

  公开（公告）日：2007-01-18

  Hydroxylated nebivolol metabolites increase NO release from human endothelial cell preparations in a concentration dependent fashion following acute administration. In addition, hydroxylated nebivolol metabolites, including but not limited to 4-hydroxy-6,6′difluoro-, 4-hydroxy-5-phenol-6,6′difluoro-, and 4-hydroxy-8-pheno-6,6′difluoro-, have the ability to increase the capacity for NO release in human endothelial cells following chronic administration. This invention provides hydroxylated nebivolol metabolites and compositions comprising nebivolol and/or at least one hydroxylated metabolite of nebivolol and/or at least one additional compound used to treat cardiovascular diseases or a pharmaceutically acceptable salt thereof. In addition, this invention provides methods of treating and/or preventing vascular diseases by administering at least one hydroxylated metabolite of nebivolol that is capable of releasing a therapeutically effective amount of nitric oxide to a targeted site affected by the vascular disease. Also, this invention is directed to the treatment and/or prevention of migraine headaches administering at least one hydroxylated metabolite of nebivolol. This invention may also be used in conjunction with or as a single treatment of metabolic syndrome disorders.

  羟基化奈必洛尔代谢物在急性给药后以浓度依赖性方式增加人内皮细胞制剂的一氧化氮释放。此外，羟基化奈必洛尔代谢物，包括但不限于4-羟基-6,6'-二氟代-、4-羟基-5-苯酚-6,6'-二氟代-和4-羟基-8-苯并-6,6'-二氟代-，在慢性给药后能够增加人内皮细胞的一氧化氮释放能力。本发明提供了羟基化奈必洛尔代谢物和包含奈必洛尔和/或至少一种羟基化奈必洛尔代谢物和/或至少一种用于治疗心血管疾病的附加化合物的组合物，以及可药用的盐。此外，本发明还提供了通过给药至少一种能够释放治疗有效量的一氧化氮到受血管疾病影响的靶向部位的羟基化奈必洛尔代谢物来治疗和/或预防血管疾病的方法。本发明还涉及通过给药至少一种羟基化奈必洛尔代谢物来治疗和/或预防偏头痛。本发明还可以与治疗代谢综合征障碍的其他治疗联合使用，或作为单一治疗。
• Carotenoid analogs or derivatives for controlling connexin 43 expression
  申请人：Lockwood Fournier Samuel

  公开号：US20050009930A1

  公开（公告）日：2005-01-13

  A method of controlling (e.g., influencing or affecting) connexin 43 expression in a subject may include administering to the subject an effective amount of a pharmaceutically acceptable formulation. In some embodiments, controlling connexin 43 expression in a subject may effectively treat cardiac arrhythmia and/or cancerous and pre-cancerous cells in a subject. The pharmaceutically acceptable formulation may include a synthetic analog or derivative of a carotenoid. The subject may be administered a carotenoid analog or derivative, either alone or in combination with another carotenoid analog or derivative, or co-antioxidant formulation. The carotenoid analog may include a conjugated polyene with between 7 to 14 double bonds. The conjugated polyene may include an acyclic alkene including at least one substituent and/or a cyclic ring including at least one substituent. In some embodiments, a carotenoid analog or derivative may include at least one substituent.

  在一个主体中控制（例如，影响或影响）连接蛋白43表达的方法可能包括向该主体施用有效量的药学上可接受的配方。在某些实施例中，控制主体中连接蛋白43的表达可能有效治疗心律失常和/或癌症和癌前细胞。药学上可接受的配方可能包括类胡萝卜素的合成类似物或衍生物。可以向主体施用类胡萝卜素类似物或衍生物，单独或与另一类胡萝卜素类似物或衍生物或共抗氧化剂配方结合使用。类胡萝卜素类似物可能包括具有7到14个双键的共轭聚烯。共轭聚烯可能包括至少一个取代基的非环烯烃和/或至少一个取代基的环状环。在某些实施例中，类胡萝卜素类似物或衍生物可能包括至少一个取代基。
• Carotenoid analogs or derivatives for the inhibition and amelioration of liver disease
  申请人：Lockwood Fournier Samuel

  公开号：US20050004235A1

  公开（公告）日：2005-01-06

  A method of treating liver disease in a subject. The method may include administering to the subject an effective amount of a pharmaceutically acceptable formulation. The pharmaceutically acceptable formulation may include a synthetic analog or derivative of a carotenoid. The subject may be administered a carotenoid analog or derivative, either alone or in combination with another carotenoid analog or derivative, or co-antioxidant formulation. The carotenoid analog may include a conjugated polyene with between 7 to 14 double bonds. The conjugated polyene may include an acyclic alkene including at least one substituent and/or a cyclic ring including at least one substituent. In some embodiments, a carotenoid analog or derivative may include at least one substituent.

  一种治疗主体肝病的方法。该方法可能包括向主体施用有效量的药学上可接受的配方。药学上可接受的配方可能包括类胡萝卜素的合成类似物或衍生物。可以向主体施用类胡萝卜素类似物或衍生物，单独或与另一种类胡萝卜素类似物或衍生物或共抗氧化剂配方结合。类胡萝卜素类似物可能包括具有7到14个双键的共轭聚烯烃。共轭聚烯烃可能包括至少一个取代基的无环烯烃和/或至少一个取代基的环状环。在某些实施例中，类胡萝卜素类似物或衍生物可能包括至少一个取代基。
• Carotenoid ether analogs or derivatives for the inhibition and amelioration of disease
  申请人：Lockwood Fournier Samuel

  公开号：US20050009758A1

  公开（公告）日：2005-01-13

  A method for inhibiting and/or ameliorating the occurrence of diseases associated with reactive oxygen species, reactive nitrogen species, radicals and/or non-radicals in a subject whereby a subject is administered a carotenoid analog or derivative, either alone or in combination with another carotenoid analog or derivative, or co-antioxidant formulation. The analog or derivative is administered such that the subject's risk of experiencing diseases associated with reactive oxygen species, reactive nitrogen species, radicals and/or non-radicals may be thereby reduced. The analog or analog combination may be administered to a subject for the inhibition and/or amelioration of any disease that involves production of reactive oxygen species, reactive nitrogen species, radicals and/or non-radicals. In some embodiments, the invention may include a chemical compound including an at least partially water soluble carotenoid analog or derivative. The carotenoid analog may include a conjugated polyene with between 7 to 14 double bonds. The conjugated polyene may include a cyclic ring including at least one substituent. In some embodiments, a cyclic ring of a carotenoid analog or derivative may include at least one substituent. The substituent may be coupled to the cyclic ring with an ether functionality.

  一种抑制和/或改善与主体中的活性氧化物种、活性氮物种、自由基和/或非自由基相关疾病发生的方法，其中向主体施用类胡萝卜素类似物或衍生物，单独或与另一类胡萝卜素类似物或衍生物或共抗氧化剂配方结合。类似物或衍生物的施用使得主体发生与活性氧化物种、活性氮物种、自由基和/或非自由基相关疾病的风险可能降低。类似物或类似物组合可用于抑制和/或改善涉及活性氧化物种、活性氮物种、自由基和/或非自由基产生的任何疾病。在某些实施例中，该发明可能包括一种包括至少部分水溶性类胡萝卜素类似物或衍生物的化合物。类胡萝卜素类似物可能包括具有7到14个双键的共轭聚烯。共轭聚烯可能包括包括至少一个取代基的环状环。在某些实施例中，类胡萝卜素类似物或衍生物的环状环可能包括至少一个取代基。该取代基可能通过醚功能基与环状环相耦合。
• Carotenoid ether analogs or derivatives for controlling C-reactive protein levels
  申请人：Lockwood Fournier Samuel

  公开号：US20050049248A1

  公开（公告）日：2005-03-03

  A method of controlling (e.g., influencing or affecting) C-reactive protein levels in a subject may include administering to the subject an effective amount of a pharmaceutically acceptable formulation. The pharmaceutically acceptable formulation may include a synthetic analog or derivative of a carotenoid. The subject may be administered a carotenoid analog or derivative, either alone or in combination with another carotenoid analog or derivative, or co-antioxidant formulation. The carotenoid analog may include a conjugated polyene with between 7 to 14 double bonds. The conjugated polyene may include a cyclic ring including at least one substituent. In some embodiments, a cyclic ring of a carotenoid analog or derivative may include at least one j e substituent. The substituent may be coupled to the cyclic ring with an ether functionality.

  一种控制（例如，影响或影响）主体中C-反应蛋白水平的方法可能包括向主体施用有效量的药用可接受的配方。药用可接受的配方可能包括类胡萝卜素的合成类似物或衍生物。可以向主体施用类胡萝卜素类似物或衍生物，单独或与另一种类胡萝卜素类似物或衍生物或共抗氧化剂配方结合。类胡萝卜素类似物可能包括具有7到14个双键的共轭聚烯。共轭聚烯可能包括包括至少一个取代基的环状环。在某些实施例中，类胡萝卜素类似物或衍生物的环状环可能包括至少一个取代基。取代基可能通过醚功能与环状环偶联。